ID

34887

Description

A Pharmacokinetic Study Comparing SCT400 And Rituximab in Patients With B-cell Non-Hodgkin's Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT02456207

Link

https://clinicaltrials.gov/show/NCT02456207

Keywords

Versions (1)
  1. 2/2/19 2/2/19 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

February 2, 2019

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility B-cell Non Hodgkin's Lymphoma NCT02456207

English

Eligibility B-cell Non Hodgkin's Lymphoma NCT02456207

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. aged from 18 to 75 years;
Description

Age

Data type

boolean

Alias
UMLS CUI [1]
C0001779
2. having histologically confirmed nhl expressing cd20 antigen;
Description

Non-Hodgkin Lymphoma CD20 expressing

Data type

boolean

Alias
UMLS CUI [1,1]
C0024305
UMLS CUI [1,2]
C3888518
3. having obtained cr (complete remission) or cru (uncertain complete remisson) after the prior therapy;
Description

In complete remission Post Prior Therapy | Complete remission Uncertain Post Prior Therapy

Data type

boolean

Alias
UMLS CUI [1,1]
C0677874
UMLS CUI [1,2]
C0687676
UMLS CUI [1,3]
C1514463
UMLS CUI [2,1]
C0677874
UMLS CUI [2,2]
C0087130
UMLS CUI [2,3]
C0687676
UMLS CUI [2,4]
C1514463
4. ecog performance status of 0 to 1
Description

ECOG performance status

Data type

boolean

Alias
UMLS CUI [1]
C1520224
5. expected survival of at least ≥ 3 months;
Description

Life Expectancy

Data type

boolean

Alias
UMLS CUI [1]
C0023671
6. signed an informed consent form which was approved by the institutional review board of the respective medical center .
Description

Informed Consent

Data type

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. had received rituximab or other anti-cd20(+) monoclonal antibody treatment within 1 year before enrollment;
Description

rituximab | Anti-CD20 Antibody

Data type

boolean

Alias
UMLS CUI [1]
C0393022
UMLS CUI [2]
C3891557
2. having to be at least 4 weeks beyond prior anticancer therapy including corticosteroid, or have not recovered from significant toxicities of prior therapy;
Description

Cancer treatment Previous | Adrenal Cortex Hormones Previous | Prior Therapy Toxicity Recovery Lacking

Data type

boolean

Alias
UMLS CUI [1,1]
C0920425
UMLS CUI [1,2]
C0205156
UMLS CUI [2,1]
C0001617
UMLS CUI [2,2]
C0205156
UMLS CUI [3,1]
C1514463
UMLS CUI [3,2]
C0600688
UMLS CUI [3,3]
C2004454
UMLS CUI [3,4]
C0332268
3. participating in other clinical trial within 30 days before enrolment;
Description

Study Subject Participation Status

Data type

boolean

Alias
UMLS CUI [1]
C2348568
4. with serious hematologic dysfunction (white blood cell count of <3.0×103/ul; absolute neutrophil count of <1.5×103/ ul; platelet count of < 75×103/ul; hemoglobin level of < 8.0 g/dl); hepatic dysfunction (total bilirubin level of > 1.5×uln; aspartate amino transferase (ast) and alanine amino transferase (alt) levels of >2.5 × uln; renal dysfunction (serum creatinine level of > 1.5×uln ); and international normalized ratio (inr) and partial thromboplastin time or activated partial thromboplastin time (aptt) > 1.5 × uln (unless on therapeutic coagulation);
Description

Hematologic function Impaired | White Blood Cell Count procedure | Absolute neutrophil count | Platelet Count measurement | Hemoglobin measurement | Liver Dysfunction | Elevated total bilirubin | Aspartate aminotransferase increased | Alanine aminotransferase increased | Renal dysfunction | Serum creatinine raised | INR raised | Partial thromboplastin time increased | Prolonged activated partial thromboplastin time (aPTT) | Exception Coagulation therapy

Data type

boolean

Alias
UMLS CUI [1,1]
C0221130
UMLS CUI [1,2]
C0221099
UMLS CUI [2]
C0023508
UMLS CUI [3]
C0948762
UMLS CUI [4]
C0032181
UMLS CUI [5]
C0518015
UMLS CUI [6]
C0086565
UMLS CUI [7]
C0741494
UMLS CUI [8]
C0151904
UMLS CUI [9]
C0151905
UMLS CUI [10]
C3279454
UMLS CUI [11]
C0700225
UMLS CUI [12]
C0853225
UMLS CUI [13]
C0240671
UMLS CUI [14]
C1837411
UMLS CUI [15,1]
C1705847
UMLS CUI [15,2]
C0441509
5. had received live vaccine within 4 weeks prior to study entry;
Description

Vaccines, Attenuated

Data type

boolean

Alias
UMLS CUI [1]
C0042211
6. with other malignancies ; or central nervous system (cns) lymphoma, aids-related lymphoma; or active opportunistic infection, a serious nonmalignant disease;
Description

Cancer Other | Central nervous system lymphoma | Lymphoma, AIDS-Related | Opportunistic Infection | Disease Serious Except Malignant Neoplasms

Data type

boolean

Alias
UMLS CUI [1]
C1707251
UMLS CUI [2]
C0742472
UMLS CUI [3]
C0085090
UMLS CUI [4]
C0029118
UMLS CUI [5,1]
C0012634
UMLS CUI [5,2]
C0205404
UMLS CUI [5,3]
C0332300
UMLS CUI [5,4]
C0006826
7. seropositive for hcv antibody, or hiv antibody, or hepatitis b virus surface antigen (hbsag). hbc antibody seropositive, but hbv dna and hbsag negative patients may participle following consultation with a hepatitis expert regarding monitoring and use of hbv antiviral therapy, and provided they agree to receive treatment as indicated,
Description

Hepatitis C Antibody Seropositive | HIV Antibody Seropositive | Hepatitis B Surface Antigens Seropositive | Anti-HBc antibody Seropositive | Hbv DNA Test Negative allowed | Hepatitis B surface antigen negative allowed

Data type

boolean

Alias
UMLS CUI [1,1]
C0166049
UMLS CUI [1,2]
C0521143
UMLS CUI [2,1]
C0019683
UMLS CUI [2,2]
C0521143
UMLS CUI [3,1]
C0019168
UMLS CUI [3,2]
C0521143
UMLS CUI [4,1]
C0948759
UMLS CUI [4,2]
C0521143
UMLS CUI [5,1]
C1256114
UMLS CUI [5,2]
C1513916
UMLS CUI [5,3]
C0683607
UMLS CUI [6,1]
C0919711
UMLS CUI [6,2]
C0683607
8. recent major surgery (within 28 days prior to study entry );
Description

Major surgery

Data type

boolean

Alias
UMLS CUI [1]
C0679637
9. with a history of allergic reaction or protein product allergy including murine proteins;
Description

Allergic Reaction Proteins | Protein allergy | Hypersensitivity Murine protein

Data type

boolean

Alias
UMLS CUI [1,1]
C1527304
UMLS CUI [1,2]
C0033684
UMLS CUI [2]
C1112677
UMLS CUI [3,1]
C0020517
UMLS CUI [3,2]
C1699668
10. pregnant or lactating or not accepted birth control methods including male patients.
Description

Pregnancy | Breast Feeding | Gender Contraceptive methods Rejected

Data type

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
UMLS CUI [3,1]
C0079399
UMLS CUI [3,2]
C0700589
UMLS CUI [3,3]
C1548437
Back to the top of the page

Similar models

Eligibility B-cell Non Hodgkin's Lymphoma NCT02456207

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Age
Item
1. aged from 18 to 75 years;
boolean
C0001779 (UMLS CUI [1])
Non-Hodgkin Lymphoma CD20 expressing
Item
2. having histologically confirmed nhl expressing cd20 antigen;
boolean
C0024305 (UMLS CUI [1,1])
C3888518 (UMLS CUI [1,2])
In complete remission Post Prior Therapy | Complete remission Uncertain Post Prior Therapy
Item
3. having obtained cr (complete remission) or cru (uncertain complete remisson) after the prior therapy;
boolean
C0677874 (UMLS CUI [1,1])
C0687676 (UMLS CUI [1,2])
C1514463 (UMLS CUI [1,3])
C0677874 (UMLS CUI [2,1])
C0087130 (UMLS CUI [2,2])
C0687676 (UMLS CUI [2,3])
C1514463 (UMLS CUI [2,4])
ECOG performance status
Item
4. ecog performance status of 0 to 1
boolean
C1520224 (UMLS CUI [1])
Life Expectancy
Item
5. expected survival of at least ≥ 3 months;
boolean
C0023671 (UMLS CUI [1])
Informed Consent
Item
6. signed an informed consent form which was approved by the institutional review board of the respective medical center .
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
rituximab | Anti-CD20 Antibody
Item
1. had received rituximab or other anti-cd20(+) monoclonal antibody treatment within 1 year before enrollment;
boolean
C0393022 (UMLS CUI [1])
C3891557 (UMLS CUI [2])
Cancer treatment Previous | Adrenal Cortex Hormones Previous | Prior Therapy Toxicity Recovery Lacking
Item
2. having to be at least 4 weeks beyond prior anticancer therapy including corticosteroid, or have not recovered from significant toxicities of prior therapy;
boolean
C0920425 (UMLS CUI [1,1])
C0205156 (UMLS CUI [1,2])
C0001617 (UMLS CUI [2,1])
C0205156 (UMLS CUI [2,2])
C1514463 (UMLS CUI [3,1])
C0600688 (UMLS CUI [3,2])
C2004454 (UMLS CUI [3,3])
C0332268 (UMLS CUI [3,4])
Study Subject Participation Status
Item
3. participating in other clinical trial within 30 days before enrolment;
boolean
C2348568 (UMLS CUI [1])
Hematologic function Impaired | White Blood Cell Count procedure | Absolute neutrophil count | Platelet Count measurement | Hemoglobin measurement | Liver Dysfunction | Elevated total bilirubin | Aspartate aminotransferase increased | Alanine aminotransferase increased | Renal dysfunction | Serum creatinine raised | INR raised | Partial thromboplastin time increased | Prolonged activated partial thromboplastin time (aPTT) | Exception Coagulation therapy
Item
4. with serious hematologic dysfunction (white blood cell count of <3.0×103/ul; absolute neutrophil count of <1.5×103/ ul; platelet count of < 75×103/ul; hemoglobin level of < 8.0 g/dl); hepatic dysfunction (total bilirubin level of > 1.5×uln; aspartate amino transferase (ast) and alanine amino transferase (alt) levels of >2.5 × uln; renal dysfunction (serum creatinine level of > 1.5×uln ); and international normalized ratio (inr) and partial thromboplastin time or activated partial thromboplastin time (aptt) > 1.5 × uln (unless on therapeutic coagulation);
boolean
C0221130 (UMLS CUI [1,1])
C0221099 (UMLS CUI [1,2])
C0023508 (UMLS CUI [2])
C0948762 (UMLS CUI [3])
C0032181 (UMLS CUI [4])
C0518015 (UMLS CUI [5])
C0086565 (UMLS CUI [6])
C0741494 (UMLS CUI [7])
C0151904 (UMLS CUI [8])
C0151905 (UMLS CUI [9])
C3279454 (UMLS CUI [10])
C0700225 (UMLS CUI [11])
C0853225 (UMLS CUI [12])
C0240671 (UMLS CUI [13])
C1837411 (UMLS CUI [14])
C1705847 (UMLS CUI [15,1])
C0441509 (UMLS CUI [15,2])
Vaccines, Attenuated
Item
5. had received live vaccine within 4 weeks prior to study entry;
boolean
C0042211 (UMLS CUI [1])
Cancer Other | Central nervous system lymphoma | Lymphoma, AIDS-Related | Opportunistic Infection | Disease Serious Except Malignant Neoplasms
Item
6. with other malignancies ; or central nervous system (cns) lymphoma, aids-related lymphoma; or active opportunistic infection, a serious nonmalignant disease;
boolean
C1707251 (UMLS CUI [1])
C0742472 (UMLS CUI [2])
C0085090 (UMLS CUI [3])
C0029118 (UMLS CUI [4])
C0012634 (UMLS CUI [5,1])
C0205404 (UMLS CUI [5,2])
C0332300 (UMLS CUI [5,3])
C0006826 (UMLS CUI [5,4])
Hepatitis C Antibody Seropositive | HIV Antibody Seropositive | Hepatitis B Surface Antigens Seropositive | Anti-HBc antibody Seropositive | Hbv DNA Test Negative allowed | Hepatitis B surface antigen negative allowed
Item
7. seropositive for hcv antibody, or hiv antibody, or hepatitis b virus surface antigen (hbsag). hbc antibody seropositive, but hbv dna and hbsag negative patients may participle following consultation with a hepatitis expert regarding monitoring and use of hbv antiviral therapy, and provided they agree to receive treatment as indicated,
boolean
C0166049 (UMLS CUI [1,1])
C0521143 (UMLS CUI [1,2])
C0019683 (UMLS CUI [2,1])
C0521143 (UMLS CUI [2,2])
C0019168 (UMLS CUI [3,1])
C0521143 (UMLS CUI [3,2])
C0948759 (UMLS CUI [4,1])
C0521143 (UMLS CUI [4,2])
C1256114 (UMLS CUI [5,1])
C1513916 (UMLS CUI [5,2])
C0683607 (UMLS CUI [5,3])
C0919711 (UMLS CUI [6,1])
C0683607 (UMLS CUI [6,2])
Major surgery
Item
8. recent major surgery (within 28 days prior to study entry );
boolean
C0679637 (UMLS CUI [1])
Allergic Reaction Proteins | Protein allergy | Hypersensitivity Murine protein
Item
9. with a history of allergic reaction or protein product allergy including murine proteins;
boolean
C1527304 (UMLS CUI [1,1])
C0033684 (UMLS CUI [1,2])
C1112677 (UMLS CUI [2])
C0020517 (UMLS CUI [3,1])
C1699668 (UMLS CUI [3,2])
Pregnancy | Breast Feeding | Gender Contraceptive methods Rejected
Item
10. pregnant or lactating or not accepted birth control methods including male patients.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0079399 (UMLS CUI [3,1])
C0700589 (UMLS CUI [3,2])
C1548437 (UMLS CUI [3,3])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial